Key Events This Week
27 Jul: New 52-week high at Rs.7,451.55 and surge in call and put option activity ahead of expiry
28 Jul: All-time high reached at Rs.7,489, continuing upward momentum
29 Jul: Multiple new highs including intraday peak of Rs.7,674 and sharp open interest surge
30 Jul: New 52-week high at Rs.7,886.55 amid sectoral strength
31 Jul: Week closes at Rs.8,056.65 with a 3.06% intraday gain and new all-time high
Monday, 27 July 2026: New 52-Week High and Mixed Options Activity
Divis Laboratories Ltd began the week strongly, hitting a new 52-week high of Rs.7,451.55 on 27 July 2026. The stock closed at Rs.7,416.35, up 2.34%, outperforming the Sensex’s 1.05% gain. This price surge followed a brief two-day decline, signalling renewed investor confidence. The stock traded above all key moving averages, reinforcing a bullish technical setup.
Notably, the derivatives market showed contrasting signals. There was a surge in call option activity at strike prices of Rs.7,700 and Rs.7,800, with combined turnover exceeding Rs.23.3 lakhs, indicating bullish speculative positioning ahead of the 28 July expiry. Simultaneously, heavy put option volumes at the Rs.6,900 strike suggested increased hedging or cautious bearish bets, reflecting some investor prudence despite the strong price action.
Tuesday, 28 July 2026: All-Time High Amid Sustained Momentum
On 28 July, Divis Laboratories Ltd continued its upward trajectory, reaching a new all-time high of Rs.7,489. The stock closed marginally higher at Rs.7,420.45, gaining 0.06%, while the Sensex declined slightly by 0.14%. The stock’s outperformance within the Pharmaceuticals & Biotechnology sector was supported by strong fundamentals and technical strength, with prices remaining above all major moving averages.
Financially, the company’s recent quarterly results remained a key underpinning factor, with record net sales of Rs.2,831 crores and PBDIT of Rs.934 crores. Institutional investors’ 39.58% stake further bolstered confidence in the stock’s prospects.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Wednesday, 29 July 2026: Multiple New Highs and Open Interest Surge
Wednesday marked a significant day for Divis Laboratories Ltd, which hit an intraday high of Rs.7,674, a 3.42% increase from the previous close, and closed at Rs.7,794, up 5.03%. This represented a three-day consecutive gain streak with a cumulative return of 4.28%. The stock outperformed both its sector and the Sensex, which gained 1.02% on the day.
Derivatives activity intensified, with open interest surging 18.3% to 60,155 contracts, signalling fresh long positions and strong market participation. The futures segment alone accounted for a notional value of approximately Rs.66,051 lakhs, while options reached Rs.45,032 crore, underscoring the stock’s liquidity and investor interest.
Technical indicators remained bullish, with the stock trading above all key moving averages and supported by positive weekly MACD and Bollinger Bands. The Mojo Score stood at 71.0 with a Buy rating, upgraded earlier in July, reflecting improved fundamentals and trend assessments.
Thursday, 30 July 2026: New 52-Week High Amid Sector Strength
Divis Laboratories Ltd extended its winning streak to four days, hitting a new 52-week high of Rs.7,886.55 on 30 July 2026. The stock closed with a modest gain of 0.60%, outperforming the Pharmaceuticals & Biotechnology sector by 0.25%. This rally was supported by strong quarterly financials, including record net sales and profits, and a net-debt-free balance sheet.
The broader market was mixed, with the Sensex slipping slightly by 0.05%, but sectoral indices such as NIFTY PHARMA reached new highs, reflecting strength in the pharmaceutical space. Divis Laboratories’ market capitalisation rose to Rs.2,06,906 crores, solidifying its position as the second-largest company in the sector.
Want to dive deeper on Divis Laboratories Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Friday, 31 July 2026: Week Closes at New High with Strong Intraday Gain
Divis Laboratories Ltd capped the week with a fifth consecutive day of gains, hitting a new 52-week and all-time high of Rs.8,086.55. The stock closed at Rs.8,056.65, up 2.76% on the day and outperforming the Sensex’s 0.39% gain. This marked a cumulative weekly return of 11.18%, substantially ahead of the benchmark index.
Technical indicators remained predominantly bullish, with the stock trading above all major moving averages and supported by positive MACD and Bollinger Bands on weekly and monthly charts. The company’s Mojo Score of 71.0 and Buy rating reflect its strong fundamentals and market positioning.
Despite some mild bearish signals in weekly RSI and monthly KST, the overall trend remains upward, supported by solid quarterly results, a net-debt-free balance sheet, and significant institutional holdings of 39.58%. The stock’s premium valuation, with a price-to-book value of 12.4 and PEG ratio of 4.0, suggests investors are pricing in sustained growth and quality.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-27 | Rs.7,416.35 | +2.34% | 36,207.16 | +1.05% |
| 2026-07-28 | Rs.7,420.45 | +0.06% | 36,155.32 | -0.14% |
| 2026-07-29 | Rs.7,794.00 | +5.03% | 36,524.95 | +1.02% |
| 2026-07-30 | Rs.7,840.50 | +0.60% | 36,541.96 | +0.05% |
| 2026-07-31 | Rs.8,056.65 | +2.76% | 36,684.83 | +0.39% |
Key Takeaways
Strong Price Momentum: Divis Laboratories Ltd outperformed the Sensex by 8.79% over the week, driven by multiple new 52-week and all-time highs and a five-day consecutive gain streak.
Robust Financials: Record quarterly net sales of Rs.2,831 crores and PBDIT of Rs.934 crores, coupled with a net-debt-free balance sheet and a healthy ROE of 16.32%, underpin the stock’s rally.
Technical Strength: The stock consistently traded above all key moving averages, supported by bullish MACD, Bollinger Bands, and Dow Theory indicators on weekly and monthly timeframes.
Derivatives Market Activity: Elevated call and put option volumes ahead of expiry indicated both bullish speculative interest and cautious hedging, reflecting nuanced investor sentiment.
Valuation Premium: The stock trades at a high price-to-book value of 12.4 and PEG ratio of 4.0, suggesting investors are pricing in sustained growth despite moderate long-term sales and profit growth rates.
Conclusion
Divis Laboratories Ltd’s impressive 11.18% weekly gain, marked by multiple new highs and strong financial results, highlights its dominant position in the Pharmaceuticals & Biotechnology sector. The stock’s consistent outperformance relative to the Sensex and sector peers, combined with robust technical indicators and significant institutional backing, underscores its quality and resilience. While valuation metrics indicate a premium, the company’s net-debt-free status, operational efficiency, and positive market momentum provide a solid foundation for its elevated market standing. Investors should monitor ongoing derivatives activity and technical signals for indications of near-term volatility, but the overall trend remains bullish as the stock closes a strong week of gains.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
